Long-term treatment in rheumatoid arthritis: do biological and targeted-synthetic DMARDs increase the risk of malignancy?

Rheumatology (Oxford). 2022 May 5;61(5):1758-1759. doi: 10.1093/rheumatology/keab750.

Authors

Filippo Fagni^{1

2}, David Simon^{1

2}

Affiliations

¹ Department of Internal Medicine 3 - Rheumatology and Immunology.
² Deutsches Zentrum Immuntherapie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

PMID: 34648000
DOI: 10.1093/rheumatology/keab750

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antirheumatic Agents* / adverse effects
Arthritis, Rheumatoid* / drug therapy
Biological Products* / adverse effects
Humans
Neoplasms* / chemically induced
Neoplasms* / drug therapy

Substances

Antirheumatic Agents
Biological Products